FGFR2 amplification resulted in activated PI3K‐AKT signaling and inhibition of apoptosis.[8] FGFR2 amplification occurs in breast cancer cell lines as well as in normal breast and tumor tissues.[9, 10, 11] It has been reported that 64.8% (81/125) and 56.8% (71/125) of all breast cancers express FGFR2 in the cytoplasm and nucleus, respectively.[12] Cytoplasmic FGFR2 expression is significantly associated with tumor size as well as tumor node and metastasis (TNM) stage. Here, AKT1 is linked to neoplasm.